KLOW Blend 30mg — Vial Spec, Reconstitution Math & COA

Overview of KLOW Blend 30mg Vial Specifications and Availability

The KLOW Blend 30mg formulation represents a specialized research-grade lyophilized cake engineered for precise laboratory volumetric handling. Containing a stoichiometric ratio of four distinct bio-active peptides—BPC-157, TB-500 (Thymosin Beta-4 fragment), GHK-Cu (Glycyl-L-histidyl-L-lysine copper complex), and KPV (Lysine-Proline-Valine)—this formulation allows researchers to evaluate multi-pathway signaling simultaneously without preparing independent primary stock solutions.

Please note: PX1 Research periodically adjusts vial sizing to match high-throughput laboratory demand. While analytical methodologies for a 30mg total mass configuration are detailed below, investigators seeking high-capacity bulk workflow units can examine the primary catalog listing for the KLOW Blend 80mg. All standard peptide formats distributed by PX1 Research undergo identical synthesis, lyophilization, and third-party verification protocols regardless of total mass fill.

Synergistic Mechanism Profile of the Four Component Peptides

In preclinical model systems, the constituent peptides of the KLOW matrix target distinct yet complementary molecular signaling pathways. BPC-157 research compounds have been demonstrated in animal models to upregulate vascular endothelial growth factor (VEGF) receptor expression, promoting focal adhesion kinase (FAK) phosphorylation and downstream angiogenesis in ischemic tissues.

Simultaneously, TB-500 research protocols focus on actin monomer sequestration and cell migration dynamics. In vitro scratch assays indicate that Thymosin Beta-4 fragments enhance keratinocyte and fibroblast motility by maintaining an unpolymerized G-actin pool necessary for rapid cytoskeletal reorganization.

The inclusion of GHK-Cu copper peptide research introduces an extracellular matrix modulating signal. GHK-Cu regulates matrix metalloproteinase (MMP) transcription while stimulating collagen type I and III synthesis in cultured dermal fibroblasts. Finally, KPV peptide mechanisms suppress nuclear factor kappa B (NF-κB) translocation, mitigating pro-inflammatory cytokine cascades (TNF-α, IL-6) in cellular inflammatory challenge models. Together, these four agents provide an all-in-one matrix for evaluating tissue regeneration mechanisms in vitro.

Molecular Ratios and Mass Distribution in a 30mg Total Fill

In a standardized 30mg total peptide mass vial of KLOW Blend, the lyophilized cake is composed of mathematically controlled ratios of each constituent sequence. A typical analytical mass balance for a 30mg fill delivers a balanced distribution designed to achieve bioactive concentrations in culture media upon dilution:

1. BPC-157: 5 mg total mass (approx. 16.67% of total peptide content) 2. TB-500: 5 mg total mass (approx. 16.67% of total peptide content) 3. GHK-Cu: 15 mg total mass (50.0% of total peptide content, compensating for higher stoichiometric requirements in ECM remodeling assays) 4. KPV: 5 mg total mass (approx. 16.67% of total peptide content)

This balanced distribution ensures that when the total 30mg cake is dissolved in diluent, each peptide reaches working micromolar (μM) concentrations appropriate for cell culture media and biochemical assays without requiring separate reconstitution steps.

Reconstitution Math for 1mL, 2mL, and 3mL Diluent Volumes

Accurate reconstitution of a 30mg total peptide fill requires strict adherence to volumetric liquid handling protocols using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile PBS (phosphate-buffered saline, pH 7.4). Researchers can verify custom volumetric calculations using our dedicated interactive reconstitution calculator. Below are the target concentration values for common reconstituting volumes added to a 30mg total mass vial:

• Reconstitution with 1.0 mL Diluent: Total Peptide Concentration = 30.0 mg/mL (30.0 μg/μL) - BPC-157: 5.0 mg/mL (5.0 μg/μL) - TB-500: 5.0 mg/mL (5.0 μg/μL) - GHK-Cu: 15.0 mg/mL (15.0 μg/μL) - KPV: 5.0 mg/mL (5.0 μg/μL)

• Reconstitution with 2.0 mL Diluent: Total Peptide Concentration = 15.0 mg/mL (15.0 μg/μL) - BPC-157: 2.5 mg/mL (2.5 μg/μL) - TB-500: 2.5 mg/mL (2.5 μg/μL) - GHK-Cu: 7.5 mg/mL (7.5 μg/μL) - KPV: 2.5 mg/mL (2.5 μg/μL)

• Reconstitution with 3.0 mL Diluent: Total Peptide Concentration = 10.0 mg/mL (10.0 μg/μL) - BPC-157: 1.67 mg/mL (1.67 μg/μL) - TB-500: 1.67 mg/mL (1.67 μg/μL) - GHK-Cu: 5.0 mg/mL (5.0 μg/μL) - KPV: 1.67 mg/mL (1.67 μg/μL)

Laboratory Aliquot Planning and Freeze-Thaw Prevention

Repeated freeze-thaw cycles significantly accelerate the degradation of peptide tertiary structure and copper-chelate binding integrity, particularly for GHK-Cu and Thymosin Beta-4 fragments. Once reconstituted, the primary stock solution should be immediately divided into single-use laboratory aliquots using microcentrifuge tubes (e.g., polypropylene 0.5 mL or 1.5 mL vials).

A standard protocol for a 2.0 mL total reconstitution (15 mg/mL total concentration) involves partitioning the volume into twenty 100 μL aliquots. Each aliquot contains 1.5 mg total peptide mass (250 μg BPC-157, 250 μg TB-500, 750 μg GHK-Cu, 250 μg KPV). Store working aliquots at -20°C or -80°C until needed for assay preparation, discarding any unused portion remaining after 24 hours at room temperature.

Storage Protocols and Temperature Stability Dynamics

Lyophilized KLOW Blend 30mg vials exhibit optimum stability when stored under vacuum-sealed conditions at -20°C in a desiccated environment. Under these conditions, the un-reconstituted peptide cake maintains target purity (>99.0%) for up to 24 months from the manufacturing date.

Post-reconstitution stability varies depending on temperature and solvent medium. Reconstituted stock solutions prepared with bacteriostatic water remain stable at 2°C to 8°C (refrigerated) for up to 28 days. Avoid prolonged exposure to intense ambient light, as copper complexes like GHK-Cu are sensitive to photo-oxidation, which can lead to premature peptide dissociation.

Analytical Purity Verification: HPLC, MS, and Endotoxin Testing

To guarantee experimental consistency across cellular models, PX1 Research subjects every batch of KLOW Blend to rigorous analytical testing in ISO 17025 accredited facilities. High-Performance Liquid Chromatography (HPLC) is conducted to verify chromatographic purity, ensuring each individual peptide component meets an isolation threshold of ≥98.0%.

Mass Spectrometry (MS) is performed simultaneously to confirm the precise molecular weight of BPC-157 (1419.5 Da), TB-500 (4963.5 Da), GHK-Cu (403.9 Da), and KPV (383.5 Da). Furthermore, every production fill is subjected to Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain below strictly defined research thresholds (<0.01 EU/μg). Investigators can review specific lot analytical reports directly within our certificate of analysis repository.

Comparative Workflow: 30mg vs. 80mg Fill Size Selection

Selecting between a 30mg total fill and a larger format depends primarily on the scope of the experimental design, the frequency of assay runs, and storage limitations. The 30mg vial configuration is ideal for small-scale exploratory pilot studies, short-term cell culture series, or laboratories seeking to minimize frozen aliquot storage volume.

Conversely, laboratories performing high-throughput screening or extended longitudinal animal models often prefer larger unit sizes. Utilizing an 80mg format reduces vial-to-vial variability across large sample sets and optimizes volumetric dilution steps for automated liquid handling workstations. Principal investigators planning large-scale laboratory purchasing should explore our wholesale laboratory accounts for institutional ordering options.

Comparison with Single-Entity and Dual-Peptide Controls

When evaluating tissue restoration mechanics, researchers frequently compare the four-component KLOW Blend against isolated control groups or simplified dual-peptide matrices such as BPC-157/TB-500 blends. In vitro comparative literature suggests that while individual components stimulate targeted pathways—such as isolated GHK-Cu inducing collagen synthesis—the combination of anti-inflammatory (KPV) and pro-angiogenic (BPC-157/TB-500) signals produces a distinct gene expression profile in damaged tissue assays.

To examine complete single-agent specifications or assemble custom experimental control panels, investigators can review our full catalog of research peptides or explore dedicated mechanistic synthesis reviews in the peptide research hub.

PX1 Research Quality Commitments and Distribution Standards

PX1 Research operates strictly as a USA-manufactured supplier of ultra-pure research compounds. All synthesized peptides are processed under GMP-compliant conditions and subjected to rigorous quality management standards prior to distribution.

To support rapid experimental timelines, PX1 Research provides same-day dispatch for orders placed Monday through Friday before cut-off times, shipping directly from specialized fulfillment centers in California and Arizona. Every package is thermally insulated and protected against environmental degradation during transit, ensuring product stability upon delivery to your research facility.